Mifomet

Metformin Hydrochloride and Sitagliptin, the active ingredient in Mifomet, is a Biguanide/DPP-4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to control blood glucose levels.

GNH USA supplies Mifomet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Customers benefit from reliable logistics, comprehensive documentation, and responsive technical support throughout the procurement process.

Mifomet combines two antidiabetic agents that act on glucose metabolism and insulin secretion.

- Type 2 diabetes mellitus: improves glycaemic control when added to diet, exercise and other oral agents. - Inadequate control with metformin alone: provides additional glucose‑lowering effect through DPP‑4 inhibition. - Combination therapy in patients requiring both insulin sensitisation and enhanced incretin activity: simplifies regimen by delivering two mechanisms in one tablet.

Adverse reactions may occur with any antidiabetic therapy and should be monitored.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhoea: loose stools, usually transient. - Abdominal discomfort: cramping or pain. - Headache: mild tension‑type. - Hypoglycaemia (when combined with sulfonylureas or insulin): sweating, shakiness. - Metallic taste: transient oral sensation.

Serious or Rare Side Effects: - Lactic acidosis: severe metabolic disturbance, medical emergency. - Pancreatitis: abdominal pain with elevated enzymes. - Severe allergic reactions: rash, angioedema, anaphylaxis. - Hepatic dysfunction: jaundice, elevated liver enzymes. - Persistent hypoglycaemia: confusion, loss of consciousness. - Renal impairment worsening: accumulation of metformin.

Patients should be evaluated for contraindications and monitored during therapy. - Renal function assessment: avoid in severe renal impairment. - Hepatic disease monitoring: use cautiously in liver dysfunction. - Cardiovascular status: monitor for heart failure exacerbation. - Concomitant medications: review for drugs affecting glucose or renal clearance. - Pregnancy and lactation: discuss risks with healthcare provider. - Store at ambient temperature: keep below 25°C in original container, protect from moisture and light.

Drug interactions can modify efficacy or increase risk of adverse events.

Major Interactions (Avoid): - Insulin or sulfonylureas: heightened risk of severe hypoglycaemia. - Iodinated contrast agents: may precipitate renal dysfunction, increase metformin accumulation. - Cimetidine: can raise sitagliptin plasma levels.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of metformin. - Beta‑blockers: can mask hypoglycaemia symptoms. - ACE inhibitors/ARBs: monitor renal function when combined.